Serum C-reactive protein to albumin ratio as a reliable marker of diabetic neuropathy in type 2 diabetes mellitus

Basit Öğe Kaydı
dc.authoridAktas, Gulali/0000-0001-7306-5233
dc.contributor.authorAktas, Gulali
dc.date.accessioned2024-09-25T20:00:09Z
dc.date.available2024-09-25T20:00:09Z
dc.date.issued2024
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractIn various diseases characterized by inflammation, the C-reactive protein to albumin ratio (CAR) serves as a marker of inflammation. Type 2 diabetes mellitus (T2DM) is frequently complicated by diabetic neuropathy (DN) and timely diagnosis is crucial for treatment and potential reversal of this complication. Since both DN and T2DM are associated with chronic, low-grade inflammation, our study aimed to evaluate CAR levels in type 2 diabetic subjects with DN and compare them to those in subjects without DN. Patients presenting to our institutional outpatient clinics were divided into two groups based on the presence of DN. Data on characteristics and laboratory measures, including CAR,were compared between the DN and non-DN groups. The median CAR in the DN and non-DN groups was 2.19% (range 0.2%-49%) and 0.56% (range 0.02%-5.8%), respectively (P < 0.001). CAR showed significant positive correlations with weight (r = 0.19, P = 0.01), body mass index (BMI) (r = 0.11, P = 0.03), waist circumference (r = 0.10, P = 0.046), fasting glucose (r = 0.14, P = 0.004), serum creatinine (r = 0.25, P < 0.001), triglyceride (r = 0.17, P < 0.001), and LDL-cholesterol (r = 0.13, P = 0.001) levels, and an inverse correlation with estimated glomerular filtration rate (eGFR) (r = -0.16, P < 0.001). Additionally, CAR demonstrated a sensitivity of 78% and specificity of 73% for predicting DN at a threshold of 1.02% (area under curve [AUC] 0.84, 95% confidence interval [CI] 0.82-0.87, P < 0.001). High CAR levels were independently associated with an increased risk of DN (odds ratio [OR] 1.34, 95% CI 1.08-1.62, P < 0.001). Elevated CAR levels may thus be considered a potential marker for DN in T2DM patients.en_US
dc.identifier.doi10.17305/bb.2024.10426
dc.identifier.issn2831-0896
dc.identifier.issn2831-090X
dc.identifier.pmid38635449en_US
dc.identifier.scopus2-s2.0-85195111828en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.17305/bb.2024.10426
dc.identifier.urihttps://hdl.handle.net/20.500.12491/14099
dc.identifier.wosWOS:001267325900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevoen_US
dc.relation.ispartofBiomolecules And Biomedicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzYK_20240925en_US
dc.subjectType 2 diabetes mellitus (T2DM)en_US
dc.subjectdiabetic neuropathy (DN)en_US
dc.subjectinflammationen_US
dc.subjectC-reactive protein to albumin ratio (CAR)en_US
dc.titleSerum C-reactive protein to albumin ratio as a reliable marker of diabetic neuropathy in type 2 diabetes mellitusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu